tiprankstipranks
Analyst Profile
Followed by 4 other investors
.
John Sourbeer

John Sourbeer

UBS
Wall Street Analyst
Ranked #6,896 out of 8,047 Analysts on TipRanks (#18,446 out of 21,521 overall experts)

Success Rate

38%
6 out of 16 Profitable Transactions

Average Return

-9.80%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied John Sourbeer's ratings since 2021 and opened each position for the duration of 1 Year:
37.50% of your transactions would have been profitable with an average return of -9.8%

Stock Rating Distribution

29Ratings
55.17% Buy
44.83% Hold
0.00% Sell
Distribution of John Sourbeer's ratings

Additional Information

Main Sector:General
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
CryoPort Inc
(CYRX)
Rating Type:Buy
Dates:Aug 05, 2022 - Jan 01, 1970
Gain:14.20%
The most profitable rating made by John Sourbeer

John Sourbeer's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Ortho Clinical Diagnostics Holdings
Buy
Initiated
100%
+3.20%
1
Thermo Fisher
Buy
Reiterated
$700.00
(16.05% Upside)
50%
-0.70%
2
Avantor
Buy
Reiterated
$50.00
(75.07% Upside)
0%
-24.10%
1
Singular Genomics Systems
Buy
Reiterated
$25.00
(498.09% Upside)
0%
-51.90%
1
Illumina
Hold
Reiterated
$350.00
(68.01% Upside)
0.00%
1
IQVIA Holdings
Buy
Reiterated
$290.00
(17.98% Upside)
33%
-2.50%
3
Catalent
Buy
Reiterated
$145.00
(31.85% Upside)
50%
-2.80%
2
Charles River Labs
Buy
Reiterated
$378.00
(62.22% Upside)
0%
-13.10%
2
Zymergen
Hold
Reiterated
$2.60
(-19.50% Downside)
0.00%
3
Qiagen
Hold
Reiterated
0.00%
5
List of latest recommendations made by John Sourbeer. Click to expand and see John Sourbeer's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More